MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer

Cancer Biomarkers

Volumn 8, Issue 2, 2010, Pages 53-60

  Choschzick, Matthias ^a   Heilenkötter, Uwe ^b   Lebeau, Annette ^a   Jaenicke, Fritz ^a   Terracciano, Luigi ^c   Bokemeyer, Carsten ^a   Sauter, Guido ^a   Simon, Ronald ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Hospital Itzehoe   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

amplification; breast cancer; MDM2; prognosis

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; MYC PROTEIN; PROTEIN MDM2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 8Q; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; EARLY STAGE BREAST CANCER; FOLLOW UP; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE AMPLIFICATION; HUMANS; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL ANALYSIS;

EID: 80052604653     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/DMA-2011-0806     Document Type: Article

References (34)

1. E.B.C.T.C. Group, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet 365 (2005), 1687-1717.
2. A.K. Imkampe and T. Bates, Improvements in breast cancer survival over time, related to adjuvant treatment and node status, Eur J Surg Oncol 35 (2009), 151-155.
3. S. Paik, G. Tang, S. Shak, C. Kim, J. Baker, W. Kim, M. Cronin, F.L. Baehner, D. Watson, J. Bryant, J.P. Costantino, C.E. Geyer, Jr., D.L. Wickerham and N. Wolmark, Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer, J Clin Oncol 24 (2006), 3726-3734. (Pubitemid 46622311)
4. C. Ruiz, S. Seibt, K. Al Kuraya, A.K. Siraj, M. Mirlacher, P. Schraml, R. Maurer, H. Spichtin, J. Torhorst, S. Popovska, R. Simon and G. Sauter, Tissue microarrays for comparing molecular features with proliferation activity in breast cancer, Int J Cancer 118 (2006), 2190-2194.
5. G.R. Bignell, T. Santarius, J.C. Pole, A.P. Butler, J. Perry, E. Pleasance, C. Greenman, A. Menzies, S. Taylor, S. Edkins, P. Campbell, M. Quail, B. Plumb, L. Matthews, K. Mclay, P. A. Edwards, J. Rogers, R. Wooster, P.A. Futreal and M.R. Strat-ton, Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution, Genome Res 17 (2007), 1296-1303. (Pubitemid 47360904)
6. D.G. Albertson, Gene amplification in cancer, Trends Genet 22 (2006), 447-455. (Pubitemid 44093770)
7. S. Myllykangas, T. Bohling and S. Knuutila, Specificity, selection and significance of gene amplifications in cancer, Semin Cancer Biol 17 (2007), 42-55. (Pubitemid 46075192)
8. F.J. Esteva and G.N. Hortobagyi, Prognostic molecular markers in early breast cancer, Breast Cancer Res 6 (2004), 109-118. (Pubitemid 38607664)
9. H. Joensuu, J. Isola, M. Lundin, T. Salminen, K. Holli, V. Kataja, L. Pylkkanen, T. Turpeenniemi-Hujanen, K. Von Smitten and J. Lundin, Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study, Clin Cancer Res 9 (2003), 923-930. (Pubitemid 36323694)
10. M. Klintman, P.O. Bendahl, D. Grabau, K. Lovgren, P. Malm-strom and M. Ferno, The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in pre-menopausal patients with node-negative breast cancer, Mod Pathol 23 (2010), 251-259.
11. C.J. Ormandy, E.A. Musgrove, R. Hui, R.J. Daly and R.L. Sutherland, Cyclin D1, EMS1 and 11q13 amplification in breast cancer, Breast Cancer Res Treat 78 (2003), 323-335. (Pubitemid 36543212)
12. S. Elsheikh, A.R. Green, M.A. Aleskandarany, M. Grainge, C.E. Paish, M.B. Lambros, J.S. Reis-Filho and I.O. Ellis, CC-ND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome, Breast Cancer Res Treat 109 (2008), 325-335. (Pubitemid 351644857)
13. S.M. Rodriguez-Pinilla, R.L. Jones, M.B. Lambros, E. Ar-riola, K. Savage, M. James, S.E. Pinder and J.S. Reis-Filho, MYC amplification in breast cancer: a chromogenic in situ hybridisation study, J Clin Pathol 60 (2007), 1017-1023. (Pubitemid 47441935)
14. D.S. Haines, J.E. Landers, L.J. Engle and D.L. George, Physical and functional interaction between wild-type p53 and mdm2 proteins, Mol Cell Biol 14 (1994), 1171-1178. (Pubitemid 24036568)
15. M. Jiang, Z. Shao and Y. Zhang, [Study on p53, mdm-2 and p21WAF1 protein expression in ER-positive and ER-negative human breast cancer cell lines and its relation to biological features], Zhonghua Bing Li Xue Za Zhi 26 (1997), 327-330.
16. J. Momand, D. Jung, S. Wilczynski and J. Niland, The MDM2 gene amplification database, Nucleic Acids Res 26 (1998), 3453-3459. (Pubitemid 28347214)
17. M. Cuny, A. Kramar, F. Courjal, V. Johannsdottir, B. Iacopet-ta, H. Fontaine, J. Grenier, S. Culine and C. Theillet, Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations, Cancer Res 60 (2000), 1077-1083. (Pubitemid 30129548)
18. K. Al-Kuraya, P. Schraml, J. Torhorst, C. Tapia, B. Zaharie-va, H. Novotny, H. Spichtin, R. Maurer, M. Mirlacher, O. Kochli, M. Zuber, H. Dieterich, F. Mross, K. Wilber, R. Simon and G. Sauter, Prognostic relevance of gene amplifications and coamplifications in breast cancer, Cancer Res 64 (2004), 8534-8540. (Pubitemid 39552065)
19. C.W. Elston and I.O. Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology 19 (1991), 403-410.
20. M. Choschzick, P. Lassen, A. Lebeau, A.H. Marx, L. Terrac-ciano, U. Heilenkotter, F. Jaenicke, C. Bokemeyer, J. Izbicki, G. Sauter and R. Simon, Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome, Mod Pathol 23, 603-610.
21. S. Shousha, Oestrogen receptor status of breast carcinoma: Allred/H score conversion table, Histopathology 53 (2008), 346-347.
22. A. Marchetti, F. Buttitta, S. Girlando, P. Dalla Palma, S. Pellegrini, P. Fina, C. Doglioni, G. Bevilacqua and M. Barbareschi, mdm2 gene alterations and mdm2 protein expression in breast carcinomas, J Pathol 175 (1995), 31-38.
23. M.S. Sheikh, Z.M. Shao, A. Hussain and J.A. Fontana, The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma, Cancer Res 53 (1993), 3226-3228. (Pubitemid 23223285)
24. M. Hori, J. Shimazaki, S. Inagawa and M. Itabashi, Over-expression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer, Breast Cancer Res Treat 71 (2002), 77-83.
25. M. Phelps, M. Darley, J.N. Primrose and J.P. Blaydes, p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells, Cancer Res 63 (2003), 2616-2623. (Pubitemid 36605204)
26. M.F. Press, L. Bernstein, P.A. Thomas, L.F. Meisner, J.Y. Zhou, Y. Ma, G. Hung, R.A. Robinson, C. Harris, A. El-Naggar, D.J. Slamon, R.N. Phillips, J.S. Ross, S.R. Wolman and K.J. Flom, HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas, J Clin Oncol 15 (1997), 2894-2904. (Pubitemid 27330017)
27. M.C. Cheang, S.K. Chia, D. Voduc, D. Gao, S. Leung, J. Snider, M. Watson, S. Davies, P.S. Bernard, J.S. Parker, C.M. Perou, M.J. Ellis and T.O. Nielsen, Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer, J Natl Cancer Inst 101 (2009), 736-750.
28. T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J. S. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Deme-ter, C.M. Perou, P.E. Lonning, P.O. Brown, A.L. Borresen-Dale and D. Botstein, Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci USA 100 (2003), 8418-8423. (Pubitemid 36842560)
29. R.M. Tamimi, H.J. Baer, J. Marotti, M. Galan, L. Galaburda, Y. Fu, A.C. Deitz, J.L. Connolly, S.J. Schnitt, G.A. Colditz and L.C. Collins, Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer, Breast Cancer Res 10 (2008), R67.
30. I. Ben-Porath, M.W. Thomson, V.J. Carey, R. Ge, G.W. Bell, A. Regev and R.A. Weinberg, An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40 (2008), 499-507. (Pubitemid 351601215)
31. F. Courjal, M. Cuny, J. Simony-Lafontaine, G. Louason, P. Speiser, R. Zeillinger, C. Rodriguez and C. Theillet, Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups, Cancer Res 57 (1997), 4360-4367. (Pubitemid 27413447)
32. R. Naidu, N.A. Wahab, M.M. Yadav and M.K. Kutty, Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters, Oncol Rep 9 (2002), 409-416.
33. R. Seshadri, C.S. Lee, R. Hui, K. Mccaul, D.J. Horsfall and R.L. Sutherland, Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis, Clin Cancer Res 2 (1996), 1177-1184. (Pubitemid 26238449)
34. J.K. Kim and J.A. Diehl, Nuclear cyclin D1: an oncogenic driver in human cancer, J Cell Physiol 220 (2009), 292-296.